Dr. Nakhle Saba discussed advances in follicular lymphoma, noting BR's superiority over R-CHOP and R-Squared, and benefits of maintenance rituximab. IN-MIND and L-TAF-R trials showed strong results with tafasitamab regimens. Promising therapies include EZH2 inhibitors, bispecifics, and BTK inhibitor nemtabrutinib.